ID   L1210/Ara-C
AC   CVCL_R996
SY   L1210/ARA-C; L1210/ara C
DR   ChEMBL-Cells; CHEMBL3307421
DR   ChEMBL-Targets; CHEMBL614716
DR   PubChem_Cell_line; CVCL_R996
DR   Wikidata; Q54900956
RX   PubMed=6182115;
CC   From: Khwaja T; University of California, Los Angeles; Los Angeles; USA.
CC   Selected for resistance to: ChEBI; CHEBI:28680; Cytarabine (Arabinosylcytosine; Ara-C).
CC   Transformant: ChEBI; CHEBI:34342; 3-methylcholanthrene (3-MC; 20-methylcholanthrene; 20-MC; MCA).
CC   Derived from site: In situ; Ascites; UBERON=UBERON_0007795.
CC   Cell type: T-cell; CL=CL_0000084.
CC   Breed/subspecies: DBA/2.
DI   NCIt; C21604; Mouse leukemia
OX   NCBI_TaxID=10090; ! Mus musculus (Mouse)
HI   CVCL_0382 ! L1210
SX   Female
AG   8M
CA   Cancer cell line
DT   Created: 05-11-13; Last updated: 05-10-23; Version: 14
//
RX   PubMed=6182115; DOI=10.1002/ijc.2910300317;
RA   Momparler R.L., Momparler L.F., Samson J.;
RT   "Combinational chemotherapy of L1210 and L1210/ARA-C leukemia with
RT   5-AZA-2'-deoxycytidine and beta-2'-deoxythioguanosine.";
RL   Int. J. Cancer 30:361-364(1982).
//